CTNND1 (Ab-228) Antibody

What is CTNND1 and what functional roles does it play in cellular biology?

CTNND1 (Catenin Delta 1), also known as p120-catenin, is a multifunctional protein with fundamental roles in cellular biology. It is expressed in various cell types including vascular endothelium and is critical for normal cellular function . The protein features several alternatively spliced isoforms with tissue-specific expression patterns - melanocytes and melanoma cells predominantly express the long isoform 1A, while keratinocytes express shorter isoforms, particularly 3A . The shortest isoform, 4A, is typically found in normal keratinocytes and melanocytes but is frequently lost in cells derived from squamous cell carcinomas or melanomas .

From a functional perspective, CTNND1 plays crucial roles in cell adhesion, signal transduction, and transcriptional regulation. Recent research indicates its significant involvement in cancer progression, with altered expression contributing to metastatic phenotypes, particularly in triple-negative breast cancer (TNBC) bone metastasis . The downregulation of CTNND1 has been associated with enhanced tumor cell migration, invasion, and metastatic potential through various signaling pathways, including the PI3K/AKT/HIF-1α pathway and CXCR4 upregulation .

What are the key specifications of CTNND1 (Ab-228) Antibody?

CTNND1 (Ab-228) Antibody is a polyclonal antibody developed by immunizing rabbits with a synthesized non-phosphopeptide derived from human Catenin-δ1 surrounding the phosphorylation site of tyrosine 228 (D-N-Y(p)-G-S) . The key specifications are summarized in the following table:

How should CTNND1 (Ab-228) Antibody be stored to maintain optimal activity?

To maintain optimal activity of the CTNND1 (Ab-228) Antibody, adhere to the following storage protocol:

• Upon receipt, immediately aliquot the antibody into working volumes to minimize freeze-thaw cycles.

• Store the antibody at -20°C for short-term usage or at -80°C for long-term storage .

• Avoid repeated freeze-thaw cycles as they can significantly degrade antibody performance and lead to loss of activity .

• When retrieving from storage, thaw aliquots slowly at 4°C or on ice rather than at room temperature.

• Once thawed, keep the antibody on ice during experimental setup and return to storage promptly after use.

• For frequently used aliquots, consider adding carrier proteins (e.g., BSA) to enhance stability during short-term storage periods.

• Monitor antibody performance regularly through standard validation techniques to ensure activity is maintained across experiments.

Following these guidelines will help preserve antibody functionality, ensuring consistent and reproducible experimental results over time.

What is the optimal protocol for Western blot analysis using CTNND1 (Ab-228) Antibody?

When performing Western blot analysis with CTNND1 (Ab-228) Antibody, follow this optimized protocol for detecting the approximately 105-108 kDa CTNND1 protein :

• Sample Preparation:

  • Lyse cells in RIPA buffer containing protease and phosphatase inhibitors

  • Sonicate briefly to shear DNA and reduce sample viscosity

  • Centrifuge at 14,000×g for 15 minutes at 4°C

  • Determine protein concentration using BCA or Bradford assay

• Gel Electrophoresis and Transfer:

  • Load 20-40 μg protein per lane on a 7-10% SDS-PAGE gel (due to CTNND1's high molecular weight)

  • Run gel at 100V until adequate separation is achieved

  • Transfer proteins to PVDF membrane (preferred over nitrocellulose for high molecular weight proteins) at 30V overnight at 4°C

• Antibody Incubation:

  • Block membrane in 5% non-fat milk in TBST for 1 hour at room temperature

  • Incubate with CTNND1 (Ab-228) Antibody at 1:500-1:3000 dilution in 5% BSA in TBST overnight at 4°C

  • Wash membrane 3× for 10 minutes each with TBST

  • Incubate with HRP-conjugated secondary antibody (anti-rabbit) at 1:5000 in 5% non-fat milk in TBST for 1 hour at room temperature

  • Wash membrane 3× for 10 minutes each with TBST

• Detection and Analysis:

  • Apply ECL substrate and image using digital imaging system

  • Expect CTNND1 to appear at approximately 105-108 kDa

  • For phospho-specific analysis around Y228, consider running parallel samples with and without phosphatase treatment to confirm specificity

• Controls and Validation:

  • Include positive control (cells known to express CTNND1)

  • Run negative control (CTNND1 knockdown cells if available)

  • Consider stripping and re-probing with total CTNND1 antibody if examining phosphorylation status

This protocol can be adjusted based on specific experimental needs and sample types, with dilution optimization recommended for each new lot of antibody.

How should immunohistochemistry (IHC) be performed with CTNND1 (Ab-228) Antibody?

For optimal immunohistochemical detection of CTNND1 using the Ab-228 antibody, implement the following protocol:

• Tissue Preparation:

  • Fix tissue samples in 10% neutral buffered formalin for 24-48 hours

  • Process and embed in paraffin following standard procedures

  • Section tissues at 4-5 μm thickness and mount on positively charged slides

  • For frozen sections, fix briefly in acetone or 4% paraformaldehyde before proceeding

• Antigen Retrieval (critical for CTNND1 detection):

  • Deparaffinize sections in xylene and rehydrate through graded alcohols to water

  • Perform heat-induced epitope retrieval (HIER) using citrate buffer (pH 6.0) for 20 minutes

  • Allow slides to cool in retrieval solution for 20 minutes before proceeding

• Staining Procedure:

  • Block endogenous peroxidase activity with 3% hydrogen peroxide for 10 minutes

  • Block non-specific binding with 5% normal goat serum for 30 minutes

  • Incubate with CTNND1 (Ab-228) antibody at 1:50-1:100 dilution overnight at 4°C

  • Wash 3× with PBS or TBS

  • Apply appropriate HRP-conjugated secondary antibody for 30 minutes at room temperature

  • Wash 3× with PBS or TBS

  • Develop signal using DAB substrate for 5-10 minutes (monitor microscopically)

  • Counterstain with hematoxylin, dehydrate, clear, and mount

• Controls and Validation:

  • Include positive control tissue (vascular endothelium is recommended as it expresses CTNND1 )

  • Run negative control by omitting primary antibody or using non-immune rabbit IgG

  • For TNBC studies, consider including bone metastasis samples as CTNND1 expression is typically reduced in these tissues

• Result Interpretation:

  • Evaluate subcellular localization (typically membrane-associated and cytoplasmic)

  • Assess staining intensity using a standardized scoring system (0-3+)

  • Quantify percentage of positive cells and correlate with clinical parameters if applicable

This protocol can help researchers effectively detect CTNND1 in tissue samples while minimizing background and non-specific staining.

How can CTNND1 (Ab-228) Antibody be used to investigate the phosphorylation status of Catenin-δ1?

While CTNND1 (Ab-228) Antibody recognizes an epitope around the tyrosine 228 phosphorylation site, it was specifically generated against a non-phosphopeptide . This makes it particularly valuable for investigating phosphorylation dynamics through comparative approaches:

This methodological framework enables researchers to comprehensively investigate CTNND1 phosphorylation dynamics in various cellular contexts, including cancer progression models where CTNND1 function appears critically regulated by post-translational modifications.

How can researchers study the role of CTNND1 in cancer metastasis mechanisms?

Based on recent findings about CTNND1's involvement in cancer metastasis, particularly in triple-negative breast cancer bone metastasis , researchers can employ several methodological approaches:

• Knockdown/Knockout Studies:

  • Generate CTNND1 knockdown cell lines using shRNA or CRISPR-Cas9 approaches

  • Validate knockdown efficiency using CTNND1 (Ab-228) Antibody in Western blots

  • Assess phenotypic changes in migration, invasion, and metastatic potential

  • Analyze specific parameters:

    • Cell-cell adhesion strength using dispase assays

    • Migration capacity through wound healing assays

    • Invasion capabilities via Transwell Matrigel invasion assays

    • Metastatic potential using orthotopic xenograft models with measurement of circulating tumor cells

• Signaling Pathway Analysis:

  • Investigate the CTNND1-CXCR4 axis using flow cytometry and Western blot analyses

  • Examine PI3K/AKT/HIF-1α pathway activation in CTNND1-knockdown cells vs. controls

  • Use pharmacological inhibitors of these pathways to determine rescue effects

  • Perform co-immunoprecipitation studies to identify protein interaction partners using CTNND1 (Ab-228) Antibody

• In Vivo Metastasis Models:

  • Establish orthotopic TNBC xenograft models with CTNND1-manipulated cells

  • Monitor bone metastasis development using bioluminescence imaging

  • Analyze metastatic lesions by μCT scanning to quantify osteolytic bone lesions

  • Perform histological analysis of bone samples using H&E and IHC staining to confirm metastasis

• Microenvironment Interaction Studies:

  • Analyze neutrophil infiltration in bone metastatic lesions using flow cytometry

  • Conduct co-culture experiments with bone marrow-derived cells and CTNND1-knockdown tumor cells

  • Investigate chemokine production profiles using multiplexed cytokine assays

  • Examine extracellular matrix remodeling through zymography and collagen degradation assays

• Correlation with Clinical Samples:

  • Compare CTNND1 expression in primary tumors versus matched metastatic samples using IHC with CTNND1 (Ab-228) Antibody

  • Correlate expression patterns with patient outcomes and metastatic potential

  • Create tissue microarrays containing samples from multiple patients at various disease stages

This comprehensive approach allows researchers to thoroughly investigate CTNND1's role in cancer metastasis from molecular mechanisms to in vivo relevance and clinical significance.

How does CTNND1 interact with the CXCR4 signaling pathway and what methodologies can be used to study this interaction?

The relationship between CTNND1 and CXCR4 represents an important signaling axis in cancer metastasis, particularly in triple-negative breast cancer . To investigate this interaction, researchers can implement the following methodological approaches:

• Expression Correlation Analysis:

  • Analyze CTNND1 and CXCR4 expression levels in CTNND1-knockdown cells using:

    • Western blot with CTNND1 (Ab-228) Antibody and anti-CXCR4 antibodies

    • qRT-PCR to determine if regulation occurs at transcriptional level

    • Flow cytometry to quantify CXCR4 surface expression

  • Establish dose-dependent relationships by creating cell lines with variable CTNND1 expression levels

• Pathway Dissection Experiments:

  • Investigate the PI3K/AKT/HIF-1α pathway as the mediator between CTNND1 and CXCR4 :

    • Treat cells with PI3K inhibitors (e.g., LY294002), AKT inhibitors (e.g., MK-2206), or HIF-1α inhibitors

    • Monitor effects on CXCR4 expression in CTNND1-knockdown versus control cells

    • Analyze phosphorylation status of pathway components using phospho-specific antibodies

    • Perform ChIP assays to assess HIF-1α binding to the CXCR4 promoter

• Functional Migration/Chemotaxis Assays:

  • Conduct chemotaxis assays using CXCL12 (SDF-1), the ligand for CXCR4:

    • Compare migration of CTNND1-knockdown cells versus controls toward CXCL12 gradients

    • Assess invasion capacity through Matrigel-coated transwells with CXCL12 as chemoattractant

    • Include CXCR4 antagonists (e.g., AMD3100) to confirm specificity

  • Perform live-cell imaging to track migration dynamics and directional persistence

• In Vivo Mechanistic Studies:

  • Establish orthotopic xenograft models with CTNND1-knockdown cells

  • Treat a subset of animals with CXCR4 antagonists

  • Monitor metastatic burden through bioluminescence imaging

  • Analyze bone metastatic lesions through histopathology and μCT

  • Quantify neutrophil infiltration in metastatic sites through flow cytometry and IHC

• Co-localization and Protein Interaction Studies:

  • Perform immunofluorescence co-localization studies for CTNND1 and CXCR4

  • Conduct proximity ligation assays to detect close physical associations

  • Utilize FRET or BRET approaches to measure protein-protein interactions in live cells

  • Execute pull-down assays to identify potential adaptor proteins linking CTNND1 to CXCR4 signaling

This methodological framework allows comprehensive investigation of the CTNND1-CXCR4 axis from molecular mechanisms to functional outcomes in cancer metastasis.

What are common causes of high background or non-specific signals when using CTNND1 (Ab-228) Antibody?

When working with CTNND1 (Ab-228) Antibody, researchers may encounter high background or non-specific signals that can complicate data interpretation. Here are methodological approaches to identify and resolve these issues:

• Western Blot Background Issues:

  • Problem: Diffuse bands or multiple non-specific bands

    • Solution: Optimize antibody dilution (start with 1:1000 and adjust as needed)

    • Solution: Increase blocking stringency (5% BSA or 5% milk in TBST for 2 hours)

    • Solution: Extend wash steps (4-5 washes for 10 minutes each with TBST)

  • Problem: High membrane background

    • Solution: Pre-incubate antibody with 5% BSA in TBST for 30 minutes before application

    • Solution: Add 0.1% Tween-20 to antibody diluent

    • Solution: Use fresh transfer buffers and ensure proper transfer conditions

• IHC Background Problems:

  • Problem: Diffuse tissue staining

    • Solution: Dilute primary antibody further (try 1:100-1:200)

    • Solution: Optimize antigen retrieval (test citrate pH 6.0 vs. EDTA pH 9.0)

    • Solution: Include additional blocking steps (avidin/biotin blocking for biotin-based detection)

  • Problem: Edge artifacts or tissue damage

    • Solution: Ensure proper fixation time (24-48 hours in 10% NBF)

    • Solution: Optimize sectioning technique and section thickness

    • Solution: Store slides properly before staining to prevent section lifting

• Cross-Reactivity Challenges:

  • Problem: Detection of non-CTNND1 proteins

    • Solution: Validate antibody specificity using CTNND1 knockdown/knockout samples

    • Solution: Perform competition experiments with immunizing peptide

    • Solution: Use positive controls with known CTNND1 expression levels

• Phosphorylation-Specific Challenges:

  • Problem: Difficulty distinguishing phosphorylation-dependent signals

    • Solution: Include phosphatase-treated controls

    • Solution: Compare results with phospho-specific antibodies

    • Solution: Create appropriate positive controls using Src activators

• Methodological Optimizations:

  • Implement extended blocking steps (2 hours at room temperature)

  • Consider using alternative blocking agents (fish gelatin or commercial blockers)

  • For neuronal tissues or tissues with high endogenous biotin, use biotin blocking kits

  • When detecting low-abundance targets, consider signal amplification systems (TSA)

  • For experiments requiring high signal-to-noise ratios, monoclonal antibodies may offer advantages

By systematically addressing these potential issues, researchers can significantly improve signal specificity and data quality when working with CTNND1 (Ab-228) Antibody.

How should researchers interpret variations in CTNND1 molecular weight across different experimental systems?

Researchers frequently observe variations in the apparent molecular weight of CTNND1 across different experimental systems, which can complicate data interpretation. Here's a methodological approach to understanding and addressing these variations:

• Expected Molecular Weight Profile:

  • The calculated molecular weight of CTNND1 is approximately 108 kDa

  • Observed molecular weight typically ranges from 105-120 kDa depending on experimental conditions

  • Multiple bands may represent different isoforms or post-translational modifications

• Common Causes of Molecular Weight Variations:

  a) Alternative Splicing:

  • CTNND1 exists in multiple isoform variants (1A, 3A, 4A, etc.)

  • Melanocytes and melanoma cells primarily express long isoform 1A

  • Keratinocytes express shorter isoforms, especially 3A

  • The shortest isoform 4A is found in normal keratinocytes and melanocytes but often lost in squamous cell carcinomas or melanomas

  b) Post-translational Modifications:

  • Phosphorylation at multiple sites including Y228 can increase apparent molecular weight

  • Glycosylation patterns may vary between cell types and culture conditions

  • Ubiquitination can result in higher molecular weight species or laddering patterns

  c) Tissue-Specific Expression:

  • The C-terminal alternatively spliced exon B is present in p120ctn transcripts in colon, intestine, and prostate

  • This exon is frequently lost in tumor tissues derived from these organs

• Methodological Approaches to Resolve Variations:

  a) Gel System Optimization:

  • Use gradient gels (4-12%) for better resolution of high molecular weight proteins

  • Run gels at lower voltage (80-100V) for longer periods to improve separation

  • Consider using Phos-tag™ gels to specifically resolve phosphorylated species

  b) Validation Experiments:

  • Perform phosphatase treatment to collapse phosphorylated bands

  • Use isoform-specific antibodies when available to identify specific variants

  • Include recombinant CTNND1 protein standards as molecular weight references

  c) Complementary Techniques:

  • Confirm identity through mass spectrometry after immunoprecipitation

  • Use RT-PCR to identify which isoforms are expressed in your experimental system

  • Perform 2D gel electrophoresis to separate based on both isoelectric point and molecular weight

• Interpretation Framework:

  • Higher molecular weight than expected (>120 kDa) may indicate hyperphosphorylation or other modifications

  • Multiple discrete bands suggest the presence of different isoforms or differentially modified forms

  • Shifts in banding patterns following drug treatments may indicate changes in post-translational modifications

  • Loss of specific bands in disease samples may indicate dysregulation of splicing machinery

By applying this systematic approach, researchers can properly interpret CTNND1 molecular weight variations and extract meaningful biological insights from these observations.

How can researchers address discrepancies in CTNND1 expression data between transcript and protein levels?

Researchers frequently encounter discrepancies between CTNND1 mRNA and protein expression levels. This phenomenon requires careful methodological consideration for accurate interpretation:

• Validation of Discrepancies:

  • Confirmatory Analysis:

    • Repeat protein quantification using multiple techniques (Western blot with CTNND1 (Ab-228) Antibody , ELISA, mass spectrometry)

    • Verify mRNA measurements using different primer sets targeting various exons

    • Ensure proper normalization controls for both protein (β-actin, GAPDH) and RNA (housekeeping genes)

  • Time-Course Experiments:

    • Monitor both mRNA and protein levels over time following stimulation

    • Establish temporal relationships between transcript and protein changes

    • Consider protein half-life in interpretation (longer-lived proteins may show delayed responses)

• Biological Mechanisms Explaining Discrepancies:

  a) Post-transcriptional Regulation:

  • Investigate miRNA regulation of CTNND1 mRNA

    • Perform in silico analysis to identify potential miRNA binding sites

    • Validate through luciferase reporter assays with 3'UTR constructs

    • Manipulate candidate miRNAs through mimics or inhibitors

  • Examine mRNA stability factors

    • Perform actinomycin D chase experiments to measure mRNA half-life

    • Investigate RNA-binding proteins that may stabilize or destabilize CTNND1 transcripts

  b) Translational Control:

  • Analyze polysome profiles to assess translation efficiency

  • Investigate upstream open reading frames (uORFs) in the 5'UTR that may regulate translation

  • Examine stress responses that might influence global or transcript-specific translation

  c) Protein Stability Regulation:

  • Measure protein half-life using cycloheximide chase experiments

  • Investigate proteasomal degradation with inhibitors (MG132)

  • Examine ubiquitination status through immunoprecipitation followed by ubiquitin blotting

• Experimental Approaches to Resolve Discrepancies:

  a) Cell-Type Specific Analysis:

  • Different cell types may employ distinct post-transcriptional regulatory mechanisms

  • Compare primary cells vs. cell lines from the same tissue

  • Examine normal vs. cancer cells (particularly relevant given CTNND1's role in cancer progression)

  b) Subcellular Fractionation:

  • Sequestration in different compartments may affect protein detection

  • Separate nuclear, cytoplasmic, and membrane fractions

  • Quantify CTNND1 in each fraction to account for redistribution rather than expression changes

  c) Epitope Masking Considerations:

  • Post-translational modifications might mask the antibody epitope

  • Test multiple antibodies targeting different regions of CTNND1

  • Consider native vs. denaturing conditions for protein analysis

• Technical Troubleshooting:

  • Ensure antibody validation in your specific experimental system

  • Consider sample preparation differences (protein extraction methods may affect yield)

  • Verify primer specificity for different CTNND1 isoforms

  • Account for normalization discrepancies in high-throughput data

By systematically addressing these considerations, researchers can better understand the molecular mechanisms governing CTNND1 expression and reconcile apparently contradictory data between transcript and protein levels.

What emerging techniques show promise for studying CTNND1 phosphorylation dynamics?

As research into CTNND1 signaling advances, several cutting-edge techniques are emerging as valuable tools for studying phosphorylation dynamics at tyrosine 228 and other sites:

• Phospho-Proteomic Mass Spectrometry:

  • Employ tandem mass tag (TMT) labeling to quantitatively compare phosphorylation profiles across conditions

  • Implement parallel reaction monitoring (PRM) for targeted detection of specific CTNND1 phosphopeptides

  • Utilize titanium dioxide (TiO₂) enrichment or immunoaffinity purification with CTNND1 (Ab-228) Antibody to enhance detection of low-abundance phosphopeptides

  • Apply phospho-enrichment strategies combined with data-independent acquisition (DIA) mass spectrometry for comprehensive phosphosite mapping

• Live-Cell Phosphorylation Sensors:

  • Design FRET-based biosensors incorporating segments of CTNND1 containing Y228

  • Develop genetically encoded biosensors using split fluorescent proteins that reassemble upon phosphorylation

  • Apply optogenetic approaches to temporally control kinase activity and monitor resulting CTNND1 phosphorylation

  • Implement biosensor arrays for high-throughput screening of compounds affecting CTNND1 phosphorylation

• Single-Cell Phosphorylation Analysis:

  • Employ mass cytometry (CyTOF) with metal-conjugated CTNND1 (Ab-228) Antibody and phospho-specific antibodies

  • Implement imaging mass cytometry to preserve spatial information in tissue contexts

  • Utilize single-cell Western blotting techniques for heterogeneity assessment

  • Apply multiplexed ion beam imaging (MIBI) for high-parameter spatial analysis of CTNND1 phosphorylation in tissues

• Proximity Labeling Approaches:

  • Use BioID or TurboID fused to CTNND1 to identify proximal proteins under various phosphorylation states

  • Implement APEX2-based proximity labeling for temporal resolution of interaction changes upon phosphorylation

  • Combine with quantitative proteomics to identify phosphorylation-dependent interaction partners

  • Develop split-BioID systems to capture transient interactions during signaling events

• CRISPR-Based Genomic Engineering:

  • Generate phosphomimetic (Y228E) and phospho-deficient (Y228F) CTNND1 knock-in cell lines using CRISPR-Cas9

  • Create reporter knock-in lines expressing tagged CTNND1 from the endogenous locus for physiological expression levels

  • Apply base editing or prime editing technologies for precise modification of phosphorylation sites

  • Implement CRISPR activation/interference systems to modulate expression of kinases/phosphatases acting on CTNND1

These emerging techniques offer unprecedented resolution for studying CTNND1 phosphorylation dynamics, potentially revealing new insights into its role in cancer progression and metastasis, particularly in triple-negative breast cancer bone metastasis .

What are promising therapeutic strategies targeting CTNND1 in cancer, and how can researchers evaluate their efficacy?

Given CTNND1's role in cancer progression and metastasis, particularly in triple-negative breast cancer , several therapeutic approaches targeting CTNND1 or its associated pathways show promise. Researchers can evaluate these interventions using the following methodological framework:

• Direct CTNND1 Modulation Strategies:

  a) RNAi-Based Therapeutics:

  • Develop siRNA or shRNA delivery systems targeting CTNND1

  • Evaluate knockdown efficiency using CTNND1 (Ab-228) Antibody

  • Assessment methods:

    • Measure tumor growth inhibition in xenograft models

    • Quantify metastasis reduction through bioluminescence imaging

    • Analyze μCT parameters of bone integrity in metastasis models

  b) Small Molecule Modulators:

  • Screen for compounds that disrupt CTNND1 interactions or stability

  • Validate target engagement through cellular thermal shift assays (CETSA)

  • Assessment methods:

    • Perform high-content imaging to quantify cell-cell adhesion changes

    • Measure effects on migration and invasion through real-time cell analysis

    • Conduct pharmacokinetic/pharmacodynamic (PK/PD) studies in animal models

• Targeting CTNND1-Dependent Pathways:

  a) CXCR4 Antagonists:

  • Implement CXCR4 inhibitors (AMD3100/plerixafor) in CTNND1-low tumors

  • Assessment methods:

    • Evaluate chemotaxis inhibition in Transwell migration assays

    • Quantify metastatic burden reduction in preclinical models

    • Analyze neutrophil infiltration through flow cytometry and IHC

  b) PI3K/AKT/HIF-1α Pathway Inhibitors:

  • Test specific inhibitors of this pathway in contexts with CTNND1 downregulation

  • Assessment methods:

    • Monitor pathway inhibition through phospho-specific Western blotting

    • Measure CXCR4 expression changes by flow cytometry and qRT-PCR

    • Evaluate synergistic effects with CXCR4 antagonists

• Combinatorial Approaches:

  a) Immunotherapy Combinations:

  • Combine CTNND1/CXCR4-targeted therapies with immune checkpoint inhibitors

  • Assessment methods:

    • Analyze tumor immune infiltrate changes through multi-parameter flow cytometry

    • Perform TCR sequencing to assess T cell clonal expansion

    • Evaluate synergistic tumor control in syngeneic mouse models

  b) Conventional Therapy Enhancement:

  • Test CTNND1-targeted approaches with chemotherapy or radiation

  • Assessment methods:

    • Perform combination index analyses to quantify synergy

    • Evaluate DNA damage repair efficiency through γH2AX foci formation

    • Measure apoptotic response through annexin V/PI staining and caspase activation

• Biomarker Development for Patient Selection:

  a) Expression-Based Stratification:

  • Develop IHC protocols using CTNND1 (Ab-228) Antibody for patient tumor assessment

  • Establish scoring systems correlating with therapy response

  • Validate in retrospective and prospective clinical cohorts

  b) Pathway Activation Signatures:

  • Create gene expression signatures reflecting CTNND1-regulated pathways

  • Validate signature correlation with therapeutic response

  • Implement as companion diagnostics for clinical trials

• Resistance Mechanism Identification:

  a) Temporal Monitoring Approaches:

  • Serial sampling of patient-derived xenografts during treatment

  • Longitudinal liquid biopsy analysis for circulating tumor cells

  • Single-cell RNA sequencing to identify resistant subpopulations

  b) Functional Genomic Screens:

  • Perform CRISPR screens to identify genes conferring resistance

  • Validate hits through individual knockout/overexpression studies

  • Develop secondary combination strategies targeting resistance mechanisms

This comprehensive research framework provides a roadmap for developing and evaluating CTNND1-targeted therapies, potentially leading to novel treatment strategies for TNBC and other cancers where CTNND1 dysregulation contributes to disease progression.